![](https://library.celltelligence.com/wp-content/uploads/2022/12/Screenshot-2022-12-01-at-21.13.36.png)
$0
Allogene’s R&D Showcase 2022: Celltelligence Analysis – Part 2
On Tuesday, November 29, Allogene held an R&D showcase (press release / presentation) featuring the advances in its hematology and solid tumor programs. Below, Celltelligence provides part 2 of its analysis on Allogene’s pipeline covering its expanded solid tumor franchise and initial clinical data from ALLO-316’s (allogeneic CD70 CAR-T) while comparing Allogene’s Dagger platform to other approaches for reducing immune rejection.